ReviewPostepy dermatologii i alergologii2025
Baricitinib in the treatment of atopic dermatitis: a systematic review of randomized controlled trials.
Review in Postepy dermatologii i alergologii, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The aim of the study was to evaluate the efficacy and safety of baricitinib in treating atopic dermatitis (AD) and to provide evidence-based guidance for clinical use. Methods: Randomized controlled trials (RCTs) of baricitinib (experimental group) versus placebo (control group) were searched in PubMed and Cochrane Library databases by computer, and the search period was from the establishment of the database to December 2024. After screening the literature and extracting data, the quality of the included studies was assessed using the bias assessment tools recommended in the Cochrane Handbook for Systematic Reviews 5.1.0. Meta-analysis was conducted using RevMan 5.4 software, and sensitivity analysis and publication bias analysis were performed using Stata software. Results: A total of 6 studies were included, comprising 7 RCTs with a total of 2966 patients. The results of the meta-analysis showed that the EASI 50 or EASI 75 in the experimental group (OR = 2.68, 95% CI (2.15, 3.34), Conclusions: Baricitinib demonstrates good efficacy and safety in the treatment of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.